Dexpramipexole dihydrochloride is under clinical development by Areteia Therapeutics and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase II drugs for Chronic Obstructive Pulmonary Disease (COPD) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dexpramipexole dihydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dexpramipexole dihydrochloride overview
Dexpramipexole dihydrochloride (BIIB050, KNS760704) is under development for the treatment of eosinophilic chronic obstructive pulmonary disease (COPD) and eosinophilic asthma . The drug candidate is formulated as film coated tablet and administered through oral route. BIIB050 is the chirally pure form of dexpramipexole. It was also under development for amyotrophic lateral sclerosis (ALS) , hypereosinophilic syndrome and chronic rhinosinusitis.
Areteia Therapeutics overview
Areteia Therapeutics is a biotechnology company developing dexpramipexole, an oral medicine that inhibits the maturation of eosinophils. Areteia Therapeutics is headquartered in Bernardsville, New Jersey, the US.
For a complete picture of Dexpramipexole dihydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
